The targeted delivery of a drug should result in enhanced therapeutic efficacy with low to
minimal side effects. This is a widely accepted concept, but limited in application due to lack …

Pancreatic adenocarcinoma (PAC) remains one of the leading causes of cancer-related
death. Despite multiple advances in targeted and immune therapies, the 5-year survival in …

For many years, the medical treatment of breast cancer was reliant solely on cytotoxic
chemotherapy. However, over the past twenty years, treatment has evolved to a more target …

Gemcitabine (Gem) has been a standard first-line drug for pancreatic cancer (PCa)
treatment; however, Gem's rapid metabolism and systemic instability (short half-life) limit its …

In the past 15 years, we have seen few therapeutic advances for patients with pancreatic
cancer, which is the fourth leading cause of cancer-related death in the United States …

Oxythiamine (OT), an analogue of anti-metabolite, can suppress the nonoxidative synthesis
of ribose and induce cell apoptosis by causing a G1 phase arrest in vitro and in vivo …

Tetraiodothyroacetic acid (tetrac) and its nanoparticle formulation (Tetrac NP) act at an
integrin cell surface receptor to inhibit tumor cell proliferation and tumor-related …

Polyglutamylation is a new class of posttranslational modification in which glutamate side
chains are formed in proteins, although its biological significance is not well known. Through …

The mammalian target of rapamycin (mTOR) is an intracellular protein with a key role in
cellular protein synthesis and energy balance that influences many aspects of cell growth …

Objectives Pancreatic cancer (PC) is one of the most lethal tumors of the gastrointestinal
tract. The ability to predict which patients would benefit most from surgical intervention and …